BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Saved in:
| Title: | BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. |
|---|---|
| Authors: | Nesic K; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Krais JJ; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.; Department of Medicine Division of Oncology, Washington University School of Medicine, St Louis, MO, USA., Wang Y; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Vandenberg CJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Patel P; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Cai KQ; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Kwan T; Clovis Oncology Inc., San Francisco, CA, USA., Lieschke E; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Ho GY; School of Clinical Sciences, Monash University, Clayton, VIC, Australia., Barker HE; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Bedo J; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Casadei S; University of Washington, Seattle, WA, USA., Farrell A; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Radke M; University of Washington, Seattle, WA, USA., Shield-Artin K; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Penington JS; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Geissler F; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Kyran E; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia., Betsch R; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Xu L; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.; The University of Queensland, Brisbane, QLD, Australia., Zhang F; Department of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC, Australia., Dobrovic A; Department of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC, Australia., Olesen I; The Andrew Love Cancer Centre, Barwon Health, Geelong, VIC, Australia., Kristeleit R; Department of Oncology, Guys and St Thomas' NHS Foundation Trust, London, UK.; National Institute for Health Research, University College London Hospitals Clinical Research Facility, London, UK., Oza A; Princess Margaret Cancer Center, Toronto, ON, Canada., McNeish I; Division of Cancer, Department of Surgery & Cancer, Imperial College London, London, UK., Ratnayake G; Royal Women's Hospital, Parkville, VIC, Australia., Traficante N; Sir Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, VIC, Australia., DeFazio A; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, NSW, Australia.; The Westmead Institute for Medical Research, Sydney, NSW, Australia.; Department of Gynecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia., Bowtell DDL; Sir Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, VIC, Australia., Harding TC; Clovis Oncology Inc., San Francisco, CA, USA., Lin K; Clovis Oncology Inc., San Francisco, CA, USA., Swisher EM; University of Washington, Seattle, WA, USA., Kondrashova O; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.; The University of Queensland, Brisbane, QLD, Australia., Scott CL; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. scottc@wehi.edu.au.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. scottc@wehi.edu.au.; Royal Women's Hospital, Parkville, VIC, Australia. scottc@wehi.edu.au.; Sir Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. scottc@wehi.edu.au.; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Parkville, VIC, Australia. scottc@wehi.edu.au.; Department of Obstetrics, Gynecology and Newborn Health, University of Melbourne, Parkville, VIC, Australia. scottc@wehi.edu.au., Johnson N; Nuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Neil.Johnson@fccc.edu., Wakefield MJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. matthew.wakefield@unimelb.edu.au.; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. matthew.wakefield@unimelb.edu.au.; Department of Obstetrics, Gynecology and Newborn Health, University of Melbourne, Parkville, VIC, Australia. matthew.wakefield@unimelb.edu.au. |
| Corporate Authors: | Australian Ovarian Cancer Study |
| Source: | Molecular cancer [Mol Cancer] 2024 Aug 05; Vol. 23 (1), pp. 158. Date of Electronic Publication: 2024 Aug 05. |
| Publication Type: | Letter |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
